Belgium-based eTheRNA immunotherapies has established a collaboration and licence agreement with Ghent University for mRNA delivery with enhanced thermostability, biodegradability and safety.
eTheRNA will receive worldwide commercialisation rights for the new generation of lipid nanoparticle (LNP) formulations co-developed with the university’s research group led by Prof. Bruno De Geest, utilising combined expertise in chemistry, nanotechnology and immunology. Ionizable lipids are a main driver of LNP activity, enhancing the entrapment and stabilisation of mRNA into the LNP and facilitating the release of the mRNA payload into the cell cytoplasm where the mRNA is subsequently translated into the protein of therapeutic interest. The novel ionizable lipids offer improved biodegrability and safety, and the formulated LNPs are expected to possess a favourable thermostability profile.
“One of the bottlenecks with current mRNA pharmaceuticals is the need for elaborate cold-chain logistics. This collaboration and license agreement gives us access to lipid nanoparticles with enhanced thermostability and improved safety profiles. The new ionizable lipids with improved properties will provide the basis for our second generation of LNPs that will be used to develop future prophylactic vaccines and tumor-microenvironment modulating therapies,” commented Steven Powell, CEO at eTheRNA immunotherapies
“This partnership is the result of continuing efforts by Ghent University and Ghent University Hospital to become a leading academic and clinical center for the development of advanced therapy medicinal products (ATMPs). This LNP technology is part of our growing portfolio of ATMP related assets that we are actively developing from the bench to the bedside through our translational platform GATE,” added Dr. Dominic De Groote, Business Development Manager at Ghent University.
About eTheRNA Immunotherapies
eTheRNA immunotherapies is a clinical stage company developing mRNA immunotherapies and vaccine products for the treatment of cancer and infectious disease from its multiple RNA formulation and manufacturing technology platforms. More information on eTheRNA can be found at www.etherna.be.
About Ghent University
As one of the largest Belgian Universities in Europe, Ghent University is a leading academic and clinical centre for the active cooperation and connection of researchers and clinicians in the field of gene and cell therapy, and regenerative medicine, via the GATE (Ghent Advanced Therapies and Tissue Engineering) platform, to facilitate groundbreaking science and innovations.